A safe-haven stock with big dividends that I’d buy for my ISA

Expect financial market volatility to remain in play in the coming months, says Royston Wild. He explains why this safe haven is a great ISA buy today.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With financial markets set to remain volatile for some time yet, loading up on stable safe-haven stocks continues to be a good idea. Assura (LSE: AGR) is one such share I’d happily stash my ISA cash into.

Healthcare stocks are some of those most popular targets when the economy is beginning to flag. We still need drugs and critical medical services irrespective of whatever troubles are raging outside our windows. And as a creator and manager of general practitioner (or GP) surgeries and other primary healthcare facilities, this particular FTSE 250 stock is a wise buy for ISA investors in these troubled times. News in early April that “March quarter rents [are] being received in line with normal patterns” underlined the robustness of the company’s operations.

Don’t think of Assura as a stodgy defensive pick, though. Through its aggressive expansion policy, it’s putting itself in the box seat to capitalise on the UK’s ageing population and turbocharge profits growth. A mix of acquisition activity and new developments meant that it had 576 properties on its books as of December. This represented an increase of 13 from end of 2018.

Estimates show that half of Britain’s GP surgeries are not fit for purpose. The demand outlook for Assura’s state-of-the-art properties looks quite bright for the next few decades then.

A perky pipeline

Now, the Covid-19 outbreak threatens to put the brakes on Assura’s grand plans. In last month’s update, the healthcare firm advised that it is following government lockdown advice concerning its construction sites. And as a consequence, it said that it’s “prepared for delays to anticipated completion dates for our on-site developments and start dates of the immediate pipeline.”

This is a mere hindrance to the FTSE 250 firm’s growth strategy, of course, rather than a critical development. In fact Assura’s pipeline remains quite mighty. On the acquisition side, its immediate pipeline stands at £67m, while its corresponding development pipeline sits at £77m. It’s in great shape to keep expanding its estate once lockdown measures are eased.

What’s more, a recent share placing saw the property giant raise £185m last month. The move gives it scope to transact an extra £250m of property additions before the group’s loan-to-value level hits the 40% marker, a level that could see its corporate rating take a hit.

A terrific ISA buy

In the meantime, City analysts expect the healthcare play to grow annual earnings by single-digit percentages. They forecast rises of 1% and 6% for the fiscal years to March 2021 and 2022 respectively. Predictions of more profits growth underpin expectations of more dividend growth too. Thus yields sit at a chunky 3.7% and 3.9% for this year and next.

Assura commands a princely premium at current prices around 80p. A price-to-earnings (P/E) ratio of 28 times illustrates this point. But don’t turn your nose up. I reckon the firm’s safe-haven qualities, coupled with its exciting growth strategy, merit a hefty price tag. I’d happily add it to my own ISA.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Happy young female stock-picker in a cafe
Investing Articles

Operating profit up 26%! Auto Trader is leading the FTSE 100 on results day

An explosive move higher from the Auto Trader share price suggests the full-year results are good, but is the stock…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

If I’d put £2,000 in Nvidia stock when ChatGPT came out, here’s what I’d have now

Our writer looks at the eye-popping gains that Nvidia stock has made in the 18 months since the release of…

Read more »

British Pennies on a Pound Note
Investing Articles

This former penny share is up 163% in a year. Could it be worth even more?

Christopher Ruane explains some of the concerns that kept him away from a penny share before its stellar rise --…

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

I’m not convinced the Dr Martens share price is a bargain. Here’s why

After the bootmaker reported its full year results today, our writer explains why a Dr Martens share price in pennies…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Should I invest in the S&P 500 or FTSE 100?

Ben McPoland thinks one FTSE 100 stock might offer a compromise between high US market growth and cheap Footsie valuations.

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

How much passive income could I earn by investing £100 a month in UK shares?

With just a £100 monthly investment in UK dividend shares, I could achieve a decent passive income stream of over…

Read more »

Young Woman Drives Car With Dog in Back Seat
Investing Articles

Looking for cheap growth shares? Here’s a FTSE 250 stock to consider in June

Pets at Home shares still look dirt cheap, says Royston Wild. Here, he explains why the retailer might be one…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

The 3 big risks to Lloyds’ share price in 2024!

Is the Lloyds share price one of the FTSE 100's worst investor traps? Royston Wild thinks the bank's shares could…

Read more »